SEC Tracker
Get the app

BridgeBio Oncology Therapeutics BBOT

BridgeBio Oncology Therapeutics reports director resignation

Item 5.02 Executive or director change

Form
8-K
Filed
Importance
Major
  1. Dr. Yong Ben resigns as Chief Medical and Development Officer effective Jan 8, 2027
  2. Resignation not due to disagreements with company operations
  3. Dr. Pedro J. Beltran signed report as CEO

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when BridgeBio Oncology Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

The reading, claim by claim

  1. Dr. Ben's resignation was not due to any disagreement with the Company's operations, policies, or practices.
  2. The Form 8-K includes the Company's signatures and confirms the report was duly authorized.

2 of 4 claims matched the filing text.

Not found in the filing text

  • The filing was made public on November 5, 2026, and includes details about the departure of a senior officer.
  • No conflicts or disagreements were noted in the resignation.

For perspective, checked against its own source

From the 10-Q for the quarter ended June 30, 2026

  • In its 10-Q for the quarter ended June 30, 2026, BridgeBio Oncology Therapeutics, Inc. reported a net loss of $56.5 million.
  • This figure is directly stated in the financial statements section of the 10-Q filing.

From the filing

Item 5.02.

Item 5.02.

Departure of Director or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b)

On October 30, 2026, Yong Ben, M.D., M.B.A. provided notice of his resignation as the Chief Medical and Development Officer of BridgeBio Oncology Therapeutics, Inc. (the "Company"), effective January 8, 2027. Dr. Ben's resignation was not due to any disagreement regarding the operations, policies or practices of the Company1.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized2.

BRIDGEBIO ONCOLOGY THERAPEUTICS, INC.

Date: November 5, 2026

By:

/s/ Pedro J. Beltran, Ph.D.

Name:

Pedro J. Beltran, Ph.D.

Title:

Chief Executive Officer

Similar companies

Same SIC code (2834) and public float $300M to $2B, nearest public float first, as each company reports it on its annual report cover.

  1. KalVista Pharmaceuticals KALV public float $499M, Jun 30, 2025
  2. CytoDyn CYDY public float $418M, Nov 30, 2025
  3. Cryoport CYRX public float $400M, Jun 30, 2025
  4. Capricor Therapeutics CAPR public float $399M, Jun 30, 2025
  5. Elite Pharmaceuticals ELTP public float $534M, Sep 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.